Docetaxel (HB1801)

Small molecule

Filedunder review

Evidence outlook · regulatory review

HER2-Positive Breast Cancer: application under NMPA review

NMPA accepted the NDA for anbenitamab plus HB1801 in first-line HER2-positive advanced breast cancer, with priority review (2026-08-18). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Latest reported trial: Neo-Healer (NCT06747338) · Phase 3 · met primary endpoint · grade pending

Also in development:Non-Small Cell Lung Cancer · Phase 2/3

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (4)
HER2-Positive Breast Cancer
Other / comorbidity
NCT07805135 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2026-08-31 – 2029-06-01 · HER2-Negative Advanced Breast Cancer
What this study did
Phase 2/3 (1)
Non-Small Cell Lung Cancer
NCT06319313 · Shanghai JMT-Bio Inc.
2024-05-01 – 2027-12-01 · Squamous Cell Non-small Cell Lung Cancer
What this study did
Phase 2 (5)
HER2-Positive Breast Cancer
NCT05582499 · Fudan University
2022-11-01 – 2029-09 · Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07116824 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2025-09-15 – 2027-11-07 · HER2-positive Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06525350 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2024-07 – 2028-06-25 · Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
What this study did
NCT05863325 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2023-06-27 – 2024-09 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07083505 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2025-08-15 – 2026-12-31 · Advanced Breast Cancer
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1/2 (1)
Other / comorbidity
NCT06682611 · Shanghai Runshi Pharmaceutical Technology Co., Ltd
2024-11-13 – 2027-11-13 · Unresectable Locally Advanced or Metastatic Solid Tumors
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for HER2-Positive Breast Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Docetaxel (HB1801): this drugPhase 3Small moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
Ixabepilone
Approved(overall)
Small moleculeMicrotubules (tubulin)
Partial signal(overall)
No reviewed efficacy summary in this indication
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistReliable signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT03523585: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
PyrotinibPhase 3Small moleculeEGFR/HER1, HER2, HER4not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2Partial signal
NCT06265428: NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis.
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabPhase 3Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
BizrolertinibPhase 2/3Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 2/3Antibody–drug conjugateHER2Partial signal
NCT03500380: Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91).
EvorpaceptPhase 2Protein / enzyme therapeuticCD47not yet gradedNo reviewed efficacy summary in this indication
BBO-10203
Phase 1(overall)
Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Sabizabulin
Discontinued
Small moleculeMicrotubules (tubulin)
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Docetaxel (HB1801) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 3HER2-Positive Breast CancerActive not recruiting
Est. primary completion 2026-12-16 · NCT06747338 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-25 · NCT06525350 · CT.gov ↗
What to watch
2027 (1)
December 2027 (1)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Phase 3HER2-Negative Advanced Breast CancerNot yet recruiting
Est. primary completion 2028-06-01 · NCT07805135 · CT.gov ↗
What to watch
2034 (1)
August 2034 (1)
Phase 3HER2-Positive Breast CancerRecruiting
Est. primary completion 2034-08-07 · NCT07441460 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 August 2026Filing acceptedNMPA accepted the NDA for anbenitamab plus HB1801 in first-line HER2-positive advanced breast cancer, with priority review
CN, NMPA · Source ↗
4 August 2026Filing acceptedNMPA accepts the NDA for anbenitamab (KN026) with docetaxel for injection (albumin-bound) (HB1801) as neoadjuvant therapy, with priority review
CN, NMPA · CSPC Pharmaceutical Group · Source ↗
10 June 2026Topline resultKN026-003 Phase III meets PFS primary endpoint
CSPC Pharmaceutical Group Limited · Source ↗